Since Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) and Adverum Biotechnologies Inc. (NASDAQ:ADVM) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership of both companies.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Enanta Pharmaceuticals Inc.||89||6.38||N/A||3.71||20.20|
|Adverum Biotechnologies Inc.||8||874.45||N/A||-1.12||0.00|
Table 1 shows gross revenue, earnings per share and valuation of the two companies.
Table 2 shows us Enanta Pharmaceuticals Inc. and Adverum Biotechnologies Inc.’s net margins, return on assets and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|Enanta Pharmaceuticals Inc.||0.00%||19.3%||18.2%|
|Adverum Biotechnologies Inc.||0.00%||-33.4%||-30.8%|
Volatility and Risk
Enanta Pharmaceuticals Inc. has a beta of 0.97 and its 3.00% less volatile than Standard and Poor’s 500. Adverum Biotechnologies Inc. has a 2.43 beta and it is 143.00% more volatile than Standard and Poor’s 500.
20.7 and 20.7 are the respective Current Ratio and a Quick Ratio of Enanta Pharmaceuticals Inc. Its rival Adverum Biotechnologies Inc.’s Current and Quick Ratios are 18.2 and 18.2 respectively. Enanta Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Adverum Biotechnologies Inc.
Institutional and Insider Ownership
Roughly 91% of Enanta Pharmaceuticals Inc. shares are held by institutional investors while 76% of Adverum Biotechnologies Inc. are owned by institutional investors. Enanta Pharmaceuticals Inc.’s share held by insiders are 5.5%. Insiders Competitively, held 11.22% of Adverum Biotechnologies Inc. shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Enanta Pharmaceuticals Inc.||-8.31%||-12.8%||-12.18%||-5.06%||-22.96%||5.92%|
|Adverum Biotechnologies Inc.||-8.28%||15.9%||106.94%||342.57%||185.32%||325.71%|
For the past year Enanta Pharmaceuticals Inc. has weaker performance than Adverum Biotechnologies Inc.
On 6 of the 8 factors Enanta Pharmaceuticals Inc. beats Adverum Biotechnologies Inc.
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The companyÂ’s research and development focuses on four disease targets: Hepatitis C virus (HCV), Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). Its lead product is paritaprevir, a protease inhibitor designed for use against HCV. The company also develops HCV protease inhibitor in phase III development with AbbVie, as well as a HCV program using a different class of molecules known as cyclophilin inhibitors. In addition, it has a program in non-alcoholic steatohepatitis; and discovers programs in other areas of viral infection and liver disease. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has a pipeline that includes product candidates to treat wet age-related macular degeneration (wAMD), alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. Its lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT. The company is also developing ADVM-053 to treat hereditary angioedema; and other product candidates, such as ocular therapeutics, including AVA-311 for the treatment of juvenile X-linked retinoschisis. It has collaboration agreements with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products for ophthalmic diseases; and Editas Medicine, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.